Nanotechnology-based strategies as novel therapies in gliomas

• Published in: Therapeutic delivery Vol. 9; no. 8; pp. 571 - 592
• Main Authors: Gaikwad, Puja S, Banerjee, Rinti
• Format: Journal Article
• Language: English
• Published: England Future Science Ltd 01.08.2018; Newlands Press 01.08.2018
• Subjects: Antineoplastic Agents - administration & dosage; Bioavailability; Biomedical materials; Blood-brain barrier; Brain cancer; Brain Neoplasms - drug therapy; Brain Neoplasms - mortality; Brain Neoplasms - pathology; Cancer therapies; Chemotherapy; Clinical trials; Clinical Trials as Topic; Drug Carriers - chemistry; Drug resistance; Drug Resistance, Multiple - drug effects; Drug Resistance, Neoplasm - drug effects; enhance permeation and retention; Glioma; Glioma - drug therapy; Glioma - mortality; Glioma - pathology; gliomas; Humans; Hydrogels; Metastases; multidrug resistance; nanocarriers; Nanoparticles; Nanoparticles - chemistry; Nanotechnology; Neoplasm Recurrence, Local - mortality; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - prevention & control; Polyethylene glycol; Proteins; Quantum dots; Radiation therapy; Retention; reticuloendothelial system; Survival Rate; Theranostic Nanomedicine - methods; Theranostic Nanomedicine - trends; Topography; Treatment Outcome; Tumor cells; Tumors; multidrug resistance; reticuloendothelial system; gliomas; nanocarriers; enhance permeation and retention
• ISSN: 2041-5990; 2041-6008
• DOI: 10.4155/tde-2018-0022

Gliomas are the most common malignancies of the brain and have a mean survival of 12 months with only 5-10% of the patients surviving for more than 5 years, independent of treatment after diagnosis. Conventional treatment modalities have found the modest success in reducing tumor burden and metastases. Presence of different biological barriers and drug-resistance efflux transporters are crucial for tumor recurrence and treatment failure. Nanotechnology may amend these circumstances by targeting residual infiltrating malignant cells with minimal damage to normal cells, on-demand release and an improved cellular uptake by tumor cells. This review highlights the current status and advances in nanotechnology for treatment of gliomas.